Harrow, Inc. to acquire Viatris Inc.

Harrow, Inc. has agreed to acquire specific assets from Viatris Inc. in a healthcare sector transaction. The deal, announced on 3 August 2026, involves a headline offer of USD 30 million. Both the buyer and the target are based in the United States. The consideration for this asset sale is structured as a combination of cash and an earn-out component. This arrangement allows for a portion of the payment to be contingent on future performance metrics, aligning the interests of both parties during the transition period. The transaction represents a focused move within the pharmaceutical and healthcare industry, where asset purchases are common for streamlining portfolios or acquiring specific product lines without assuming the entirety of the seller’s corporate structure.

The deal was completed on 1 October 2026, marking the finalisation of the transfer of the agreed-upon assets. The successful conclusion of the transaction indicates that all necessary internal approvals and conditions have been met. The integration of these assets into Harrow, Inc.’s existing operations is now underway, with the company expected to benefit from the added capabilities or products acquired from Viatris Inc. The completion date confirms the timeline from announcement to closing was approximately two months. This structured approach to the acquisition highlights the strategic nature of the asset sale, ensuring a smooth handover of the relevant business units.